Only in Titles

           Search results for: Human anti hepatitis A virus IgG antibody,anti HAV ELISA Kit   

paperclip

#21914057   2011/09/14 Save this To Up

Coexistence of IgM antihepatitis A virus and IgM antihepatitis E virus in acute viral hepatitis: a prospective, multicentre study in Korea.

This study investigated the clinical, serological and molecular characteristics of coexistence of both immunoglobulin M (IgM) antihepatitis A virus (HAV) and IgM antihepatitis E virus (HEV) in acute viral hepatitis using a prospective, multicentre design. Among a total of 771 symptomatic cases with acute viral hepatitis enrolled in a Korean city from September 2006 to August 2008, coexistence of IgM anti-HAV and IgM anti-HEV was found in 43 patients (A+E group; 6%), while the existence of IgM anti-HAV alone was found in 595 patients (A group; 77%) and that of IgM anti-HEV alone in 14 patients (E group; 2%). Clinical data analysis and measurement of IgM and IgG anti-HEV were performed using two different commercial kits, and HAV RNA and HEV RNA were detected in available serum or stool samples. The clinical features of the A+E group were similar to those of the A group. HAV RNA detection rates in the A+E and A group were similar, while HEV RNA was detected only in the stool samples of the E group, not in the A+E group. Comparative testing of anti-HEV using two different ELISA kits showed markedly discordant results for IgM anti-HEV positivity and consistently low positivity for IgG anti-HEV in the A+E group. Coexistence of IgM anti-HEV measured by the Genelabs ELISA kit in the setting of hepatitis A appears to yield false-positive results in nonendemic areas of HEV infection. Diagnosis of hepatitis E using IgM anti-HEV should be made with caution.

2097 related Products with: Coexistence of IgM antihepatitis A virus and IgM antihepatitis E virus in acute viral hepatitis: a prospective, multicentre study in Korea.

Human anti-parainfluenza Human Anti-Parainfluenza Anti-Infectious Pancreati Anti-Infectious Pancreati Recombinant Hemagglutinin Avian Influenza virus H5N Avian Influenza virus H5N anti H inh human blood an HA (Influenza A Virus Hem Rabbit Anti-Polyprotein(H Recombinant Chikungunya W Recombinant Chikungunya M

Related Pathways

paperclip

#20509469   2010/05/31 Save this To Up

Seroprevalence of hepatitis A virus in patients with chronic liver disease from Kerala: impact on vaccination policy.

Hepatitis A virus (HAV) vaccination is recommended worldwide for patients with chronic liver disease to prevent decompensation due to superinfection with HAV. There are recent reports of decline in HAV seroprevalence in developing countries, where hepatitis A was considered hyperendemic. This phenomenon would have implication on policy of hepatitis A vaccination in chronic liver disease in our region. The aim of the study was to evaluate the seroprevalence of HAV antibodies in patients with chronic liver disease and to assess the relevance of hepatitis A vaccination in these patients. Three hundred patients (268 males and 32 females) with chronic liver disease, seen at the department of gastroenterology at Amrita institute of Medical Sciences and Research Centre, Cochin, were tested for the presence of IgG anti-HAV antibodies in their sera using a commercially available ELISA kit. The mean age of the patients was 53.7 years. Of these 280 patients (93.33%) tested positive for IgG anti-HAV. Routine vaccination without testing for HAV antibodies is not recommended in chronic liver disease, as there is a high prevalence of pre-existing antibodies in these patients in our region.

2318 related Products with: Seroprevalence of hepatitis A virus in patients with chronic liver disease from Kerala: impact on vaccination policy.

Anti 3 DG imidazolone Mon Liver disease spectrum ti Multiple diseases of live FIV Core Ag, recombinant Hepatitis C Virus antibod Hepatitis B Virus antibod Hepatitis B Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod

Related Pathways

paperclip

#19175178   2009/01/29 Save this To Up

[Comparison of the reliability of two ELISA kits for detecting IgM antibody against hepatitis E virus].

To study the reliability of two ELISA kits for detecting IgM antibody against hepatitis E virus (HEV).

1398 related Products with: [Comparison of the reliability of two ELISA kits for detecting IgM antibody against hepatitis E virus].

Rabbit Anti-Polyprotein(H Human anti-parainfluenza Human anti hepatitis A vi Human Anti-E Antigen of H Human Anti-Core Antigen o Beta Amyloid (1 42) High Porcine Transmissible Gas Human heparin (Hep) antib Human borrelia burgdorfer Human anti-Hepatitis B Su Human E Antigen of Hepati Human Anti-Parainfluenza

Related Pathways

paperclip

#15909855   2005/05/24 Save this To Up

Should one vaccinate patients with chronic liver disease for hepatitis A virus in India?

Hepatitis A virus (HAV) vaccination is recommended worldwide for patients with chronic liver disease to prevent decompensation due to superinfection with HAV. India being endemic for HAV, the prevalence of pre-existing antibodies against HAV due to subclinical exposure to the virus in childhood among patients with chronic liver disease may be high and, therefore, vaccination may not be needed. However, little data are available on the prevalence of HAV antibody among patients with chronic liver disease in India.

2845 related Products with: Should one vaccinate patients with chronic liver disease for hepatitis A virus in India?

Anti 3 DG imidazolone Mon Liver disease spectrum ti Multiple diseases of live FIV Core Ag, recombinant Hepatitis C Virus antibod Hepatitis B Virus antibod Hepatitis B Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod

Related Pathways

paperclip

#12502138   2002/12/27 Save this To Up

Vaccination for hepatitis A virus is not required for patients with chronic liver disease in India.

Hepatitis A virus (HAV) vaccination is recommended worldwide for patients with chronic liver disease to prevent decompensation due to superinfection with HAV. India being endemic for HAV, the prevalence of pre-existing antibodies against HAV due to subclinical exposure to the virus in childhood among patients with chronic liver disease may be high and, therefore, vaccination may not be needed. However, data are lacking on the prevalence of HAV antibody among patients with chronic liver disease in India.

1618 related Products with: Vaccination for hepatitis A virus is not required for patients with chronic liver disease in India.

MOUSE ANTI CANINE DISTEMP MOUSE ANTI BOVINE ROTAVIR Hepatitis C Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod Hepatitis A Virus antibod Hepatitis A Virus antibod MOUSE ANTI BORRELIA BURGD Anti 3 DG imidazolone Mon

Related Pathways

paperclip

#12424929   2002/11/11 Save this To Up

Serological study of hepatitis A virus infection amongst the students of a medical college in Delhi & evaluation of the need of vaccination.

Recent seroepidemiological studies have demonstrated a decrease in the seroprevalence of hepatitis A virus (HAV) infection, thereby increasing the pool of susceptible adult population. Health care workers, especially those working in paediatric wards and nurseries, are at an increased risk of developing HAV infection. The present study was undertaken to determine the prevalence of antibody against HAV (IgG anti-HAV) among a batch of medical students of the Maulana Azad Medical College, New Delhi, so as to identify the proportion of students who would be susceptible to HAV infection and hence would benefit from a vaccination programme against HAV.

2687 related Products with: Serological study of hepatitis A virus infection amongst the students of a medical college in Delhi & evaluation of the need of vaccination.

Thermal Shaker with cooli FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu Multiple organ tumor tiss Hepatitis C Virus antibod Hepatitis B Virus antibod Hepatitis B Virus antibod Hepatitis C Virus antibod

Related Pathways

paperclip

#11049092   2001/01/19 Save this To Up

The changing epidemiological pattern of hepatitis A in an urban population of India: emergence of a trend similar to the European countries.

The present study was undertaken to determine the seroprevalence of the antibody against hepatitis A virus (IgG anti-HAV) in an urban population sample from Delhi (India) and to assess any change in the epidemiological pattern of HAV infection in this part of the world. A total of 500 healthy subjects were enrolled and divided into groups on the basis of age, sex and per capita income and evaluated for the presence of IgG anti HAV antibodies using a commercially available kit. The mean age of all the subjects was 32.6 +/- 13.2 yr. and the male:female ratio was 1.5:1. The overall prevalence of IgG anti-HAV in all subjects was 71.2% (356/500). The prevalence in subjects >35 years (92.1% [186/202]) was significantly higher than that in subjects <35 years (92.1% [186/202]) was significantly higher than in subjects <35 years (57% [170/298]). No statistically significant difference was observed between male and female subjects (71.4% [217/304] vs. 70.9% [139/196]) or between subjects belonging to middle and low socioeconomic groups (68.9% [135/196] vs. 72.7% [221/304]). These findings when compared with the results that were obtained in 1982, showed a decreasing prevalence of IgG anti-HAV, most significantly in younger age groups (16-35 years). Thus, we may conclude that the seroepidemiology of hepatitis A virus infection in urban population of India seems to be changing with seroprevalence in the younger population approaching a figure similar to that of the more developed European countries.

2260 related Products with: The changing epidemiological pattern of hepatitis A in an urban population of India: emergence of a trend similar to the European countries.

FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu Multiple organ tumor tiss TCP-1 theta antibody Sour Rabbit anti PKC theta (Ab Rabbit anti PKC theta (Ab Rabbit anti PKC theta (Ab Thermal Shaker with cooli

Related Pathways